{"organizations": [], "uuid": "936181f5b1975c8be850f67fc2f5056d0fbb93e6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-zynerba-pharma-plans-to-conduct-si/brief-zynerba-pharma-plans-to-conduct-single-pivotal-study-of-zyn002-in-fragile-x-syndrome-to-support-nda-filing-idUSFWN1QN0EG", "country": "US", "domain_rank": 408, "title": "BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.105, "site_type": "news", "published": "2018-03-05T20:31:00.000+02:00", "replies_count": 0, "uuid": "936181f5b1975c8be850f67fc2f5056d0fbb93e6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-zynerba-pharma-plans-to-conduct-si/brief-zynerba-pharma-plans-to-conduct-single-pivotal-study-of-zyn002-in-fragile-x-syndrome-to-support-nda-filing-idUSFWN1QN0EG", "ord_in_thread": 0, "title": "BRIEF-Zynerba Pharma Plans To Conduct Single Pivotal Study Of ZYN002 In Fragile X Syndrome To Support NDA Filing", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-zynerba pharma", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "zynerba pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda & co", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Zynerba Pharmaceuticals Inc:\n* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION AND PLANS TO CONDUCT A SINGLE PIVOTAL STUDY OF ZYN002 IN FRAGILE X SYNDROME TO SUPPORT AN NDA FILING\n* ZYNERBA - EXPECTS TO INITIATE SINGLE PIVOTAL STUDY MID-YEAR 2018 TO SUPPORT NDA FOR ZYN002 IN FXS\n* ZYNERBA PHARMACEUTICALS SAYS FDA & CO ARE IN AGREEMENT OVER PRIMARY & KEY SECONDARY ENDPOINTS FOR ZYN002 IN FRAGILE X SYNDROME Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T20:31:00.000+02:00", "crawled": "2018-03-06T22:38:22.034+02:00", "highlightTitle": ""}